<DOC>
	<DOC>NCT01152255</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of MK6186 and the change from baseline in plasma HIV-1 RNA after seven consecutive days of dosing.</brief_summary>
	<brief_title>MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)</brief_title>
	<detailed_description />
	<criteria>Other than HIV infection, patient's baseline health is judged to be stable Patient is documented HIV1 positive Patient has not received an investigational agent or licensed ART with in the past 30 days Patient has a history of stroke, chronic seizures, or major neurological disease Patient has a history of cancer Patient has used any immune therapy agents or immunosuppressive therapy within the past month Patient requires or anticipates the use of any prescription or nonprescription drugs during the study Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or has positive Hepatitis B surface antigen Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day) Patient is an excessive smoker (more than 10 cigarettes per day) Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Treatment of HIV-1 Infection</keyword>
</DOC>